

Cite this: *RSC Chem. Biol.*, 2024,
5, 249

Cationic dextrin nanoparticles for effective intracellular delivery of cytochrome C in cancer therapy†

Ankita Sarkar, Sanchita Sarkhel, Deepali Bisht and Amit Jaiswal *

Intracellular protein delivery shows promise as a selective and specific approach to cancer therapy. However, a major challenge is posed by delivering proteins into the target cells. Despite the development of nanoparticle (NP)-based approaches, a versatile and biocompatible delivery system that can deliver active therapeutic cargo into the cytosol while escaping endosome degradation remains elusive. In order to overcome these challenges, a polymeric nanocarrier was prepared using cationic dextrin (CD), a biocompatible and biodegradable polymer, to encapsulate and deliver cytochrome C (Cyt C), a therapeutic protein. The challenge of endosomal escape of the nanoparticles was addressed by co-delivering the synthesized NP construct with chloroquine, which enhances the endosomal escape of the therapeutic protein. No toxicity was observed for both CD NPs and chloroquine at the concentration tested in this study. Spectroscopic investigations confirmed that the delivered protein, Cyt C, was structurally and functionally active. Additionally, the delivered Cyt C was able to induce apoptosis by causing depolarization of the mitochondrial membrane in HeLa cells, as evidenced by flow cytometry and microscopic observations. Our findings demonstrate that an engineered delivery system using CD NPs is a promising platform in nanomedicine for protein delivery applications.

Received 11th June 2023,
Accepted 19th November 2023

DOI: 10.1039/d3cb00090g

rsc.li/rsc-chembio

1. Introduction

In the last few decades, cancer has become one of the major reasons for world-wide mortality and it also reduces quality and well-being of life, which leads to an early death. Conventional cancer treatment mainly includes chemotherapy and radiation therapy, which collectively cause severe toxicity to normal healthy cells as well as undesirable side effects with multi-organ damage.^{1,2} For several years, researchers have been engaged in developing suitable and less toxic mediated therapies as an alternative to conventional chemotherapy and radiation therapy to combat the associated risks to healthy cells.^{3–5} The development of nanotechnology has led to the emergence of various anticancer treatment methods,^{6–9} among which therapeutic protein delivery has been deemed of utmost importance in recent times. This is because, unlike chemotherapy where the anticancer drugs are not specific to the cancer tissue and damage healthy cells, and drug resistance develops upon

repeated administration,¹⁰ a therapeutic protein offers increased specificity, selectivity, and reduced toxicity towards healthy cells.¹¹ Similarly, unlike radiation therapy, protein-based therapies do not alter the gene sequence or normal functioning of a cell.¹² Moreover, when compared to genetic drugs, proteins directly act on targets and using cells' own metabolism, it further follows the triggered signalling pathway without causing any permanent gene mutation.¹³ However, proteins are generally membrane-impermeable due to their macromolecular structure¹⁴ so they are hindered in reaching the cytosol of a cell or in some cases the absence of a specific cell-membrane receptor restricts proteins from entry to a cell.¹⁵ Proteins are also highly susceptible to enzymatic degradation or proteolysis upon cellular entry.^{16,17} Moreover, proteins cannot be administered orally due to their instability in the digestive system.¹⁵ Therefore, delivery of proteins to cells remains a challenge.

Nanotechnology has revolutionized medical fields, allowing for targeted cancer therapy through the use of nano-sized vehicles that deliver therapeutic proteins.^{18,19} This approach also utilizes the enhanced permeation and retention (EPR) effect to achieve target specificity.²⁰ However, a major challenge associated with nanocarrier systems is achieving a high protein loading efficiency with simultaneous release of protein at the target site in its active form.²¹ Many researchers have devised

School of Biosciences and Bioengineering, Indian Institute of Technology Mandi, Kamand, Mandi, 175075 Himachal Pradesh, India. E-mail: j.amit@iitmandi.ac.in

† Electronic supplementary information (ESI) available: NTA analysis of CD NPs, standard curve plot of Cyt C and cell viability plot of Cyt C + chloroquine in HeLa cells and *in vitro* cell viability assay of A549 cells treated with different concentration of Cyt C-loaded CD NPs with and without chloroquine. See DOI: <https://doi.org/10.1039/d3cb00090g>





Scheme 1 Schematic representation of (a) Cyt C-loaded CD NP synthesis and (b) the downstream pathways of apoptosis in HeLa cells upon entry.

methods for effective cargo protein encapsulation employing various kinds of nanocarriers, including liposomes,²² synthetic polymers,²³ natural polymers, polymeric micelles¹⁴ and mesoporous silica nanoparticles, in order to best achieve this aim.^{1,24–26} It is anticipated that among these, NPs generated from naturally occurring polysaccharides will find a way towards clinical usage in the treatment of cancer due to their outstanding biocompatibility and low immunogenicity.^{27,28} In particular, the use of carbohydrate-based polymeric NPs to deliver proteins is a very promising strategy due to their advantages in terms of (i) biocompatibility, (ii) biodegradability, (iii) ease of synthesis, (iv) protection of the encapsulated cargo protein from proteolysis or enzymatic degradation, and (v) controlled and sustained release of the therapeutic cargo.²⁹

Taking into account the aforementioned factors, we developed a protein delivery nanocarrier system utilizing dextrin, a naturally occurring low-molecular-weight polysaccharide derived from the partial hydrolysis of starch. Dextrin is an FDA-approved polymer categorized as generally regarded as safe (GRAS), and it is both affordable and easily obtainable.³⁰ It has been widely used in numerous applications in food, textiles, adhesives *etc.*, and clinically it is routinely used in peritoneal dialysis solution.²⁷ Our study highlights the potential of using cationic dextrin nanoparticles (CD NPs) for protein delivery in cancer therapy. We previously synthesized CD NPs for chemotherapeutic drug delivery,³¹ and in this study we demonstrated their ability to encapsulate and deliver the crucial mitochondrial protein, cytochrome *C*, to cancer cells. With its pivotal role in inducing apoptosis, the successful

delivery of cytochrome *C* using CD NPs holds great promise for targeted and effective cancer treatment.³² It facilitates the electron transport chain in the mitochondria and has been identified as the initiator of the apoptotic signalling pathway.²⁴ Only in response to an internal or external signal (such as DNA damage), Cyt *C* can leave the inner mitochondria,²¹ and it eventually triggers the caspase cascade, which in turn initiates the downstream apoptotic signalling pathway.²⁴ However, there are still some drawbacks to this method. A few cytosolic proteins that control the outer mitochondrial membrane can occasionally become mutated and dysfunctional, which prevents the release of Cyt *C* into the cytosol.³² In addition, many cancer cells attempt to avoid the self-death process by suppressing the release of cytochrome *C*.¹⁵ Therefore, by directly delivering the protein into the cytoplasm from an external source, the problem of Cyt *C* inhibition or suppression will be resolved, and there will be rapid onset of the downstream apoptotic pathway.³³

We used CD NPs to deliver Cyt *C* and induce apoptotic cell death in cancer cells (Scheme 1). CD NPs were synthesized using ionic gelation and Cyt *C* was encapsulated within the polymer matrices (Scheme 1a). However, endocytosis is the main method of cellular entrance, and endosome maturation occurs when they fuse with lysosomes, which can hinder the effectiveness of protein delivery.³⁴ To address this obstacle, we delivered chloroquine (CQ) along with the protein-loaded CD NPs to enhance endosome escape. The co-delivery of CQ with Cyt *C*-loaded CD NPs allowed the efficient release of the therapeutic protein into the cytosol and induced apoptosis, leading to cancer cell death (Scheme 1b).



2. Materials and methods

2.1. Materials

Dextrin from maize starch, glycidyltrimethylammonium chloride (GTMAC), sodium tripolyphosphate (TPP), sodium hydroxide (NaOH), cytochrome *C* from equine heart, β -mercaptoethanol, cell proliferation assay kit II (XTT), and fluoroshield with DAPI mounting media were purchased from Sigma-Aldrich. Annexin V/PI staining kit was purchased from BD. JC-1 dye was purchased from Thermo Fisher Scientific. Primary monoclonal antibodies (rabbit mAb) for western blot were purchased from CST (cell signalling technologies). Horseradish-conjugated secondary antibody (anti-rabbit origin) was purchased from Merck. ABTS substrate was purchased from SRL. Ethanol (EtOH) was purchased from Merck, Germany. DMEM culture medium, fetal bovine serum (FBS), 0.25% trypsin-ethylenediaminetetraacetic acid (EDTA), penicillin-streptomycin (Pen-Strep), and sodium pyruvate were obtained from Thermo Fisher Scientific (Gibco). Ultrapure water (resistivity = 18.2 M Ω cm) was used in all experiments.

2.1. Synthesis and characterization of Cyt *C*-encapsulated CD NPs

Dextrin was initially cationized by incorporating quaternary ammonium groups onto the polymeric backbone using GTMAC following a process reported earlier.^{31,35,36} Cyt *C* was suspended in an alkaline buffer of pH 11, higher than its pI (10.8), which made the suspended protein negatively charged. The protein suspension (500 μ g) was allowed to stir along with the polymer cationic dextrin (CD) at a concentration of 0.5 mg mL⁻¹ for 30 min to interact electrostatically with each other. This step was followed by drop-wise addition of anionic sodium tripolyphosphate (TPP) at a concentration of 2 mg mL⁻¹ to the aqueous mixture under constant stirring. The resulting Cyt *C*-loaded CD NPs were recovered by centrifugation with an equal amount of acetone added to the solution to remove excess unbound protein from the NPs in the supernatant. The % loaded amount of Cyt *C* was calculated with the standard curve using the absorbance at 409 nm through UV-vis spectroscopy with the following equation:

$$\% \text{ Loading efficiency} = \frac{\text{Final loaded concentration of Cyt } C}{\text{Initial concentration of Cyt } C \text{ used}} \times 100$$

To visualize the prepared nanoparticles under SEM, equal volumes of prepared CD-Cyt *C* NPs (500 μ L) and acetone (500 μ L) were collected in a microcentrifuge tube and centrifuged at 4000 rpm for 15 min at 4 °C. Following centrifugation, the supernatant was decanted, and the tube was air-dried for some time to remove the residual acetone. Later, 500 μ L of DI water was added to resuspend the pellet. The 100-fold diluted sample was drop-cast onto piranha-cleaned silicon wafers and air-dried overnight. The next day, samples were visualized and images were obtained under a scanning electron microscope (Nova Nano SEM450, FEI).

2.2. pH-dependent release of Cyt *C* from CD NPs

The release of Cyt *C* from CD NPs was carried out through a dialysis technique using a 100 kD MWCO dialysis membrane. Membranes containing the loaded particles were suspended in physiological and acidic buffers (pH 7.4 and 5.5, respectively) and incubated at room temperature for a designated period of time. At each time point, 1 mL of the dialysing buffer was collected and analyzed by UV-vis spectrometer to measure the concentration of released Cyt *C* ($\lambda_{\text{max}} = 409$ nm). Subsequently, equal volumes of the respective buffers were replaced each time.

2.3. Structural and functional stability of Cyt *C* before and after release from the nanoparticle

2.3.1. Structural stability of Cyt *C* at various pH conditions before and after release using circular dichroism spectroscopy.

100 μ g mL⁻¹ of Cyt *C* was dissolved in pH 5.5, 7.4, and 11 buffers. The suspended protein was kept at 4 °C for 24 h. Following incubation, the protein samples were analyzed using circular dichroism (CD) spectroscopy. UV-vis CD spectra were recorded at room temperature and acquired in the range from 250 to 320 nm, which provides information about the protein structure.

2.3.2. Functional stability of Cyt *C* via enzyme kinetics.

The enzymatic activity of the released and native Cyt *C* was evaluated by monitoring the catalytic activity of Cyt *C* for the oxidation of ABTS (2,2'-azino-bis(3-ethylbenzthiazoline-6-sulfonate)) by hydrogen peroxide.³⁷ The ABTS substrate (300 μ L), H₂O₂ (25 mM), and the released Cyt *C* (1 μ g mL⁻¹) were added to a 1 mL cuvette (total volume: 1 mL) along with acetate buffer to make up the volume. Immediate kinetic study was performed using UV-visible spectroscopy scanned at 430 nm absorbance every 30 sec for 10 min. A control experiment was performed without Cyt *C*.

2.4. Cell culture

HeLa cells and A549 cells were maintained in a 25 mm tissue culture flask in DMEM media supplemented with 10% FBS, 1% sodium pyruvate, 1% L-glutamine, 1% Pen-Strep, and 1% non-essential amino acids in a humidified incubator with 5% CO₂ at 37 °C.

2.5. FITC conjugation and cellular uptake of CD NPs

The conjugation of CD polymer with FITC was performed as reported by Sarkar *et al.*³¹ Briefly, 1 mg of FITC was mixed with 1 mg of CD polymer in a total volume of 5 ml and stirred for 6 h in dark, followed by a dialysis process to remove excess FITC from the solution. Finally, the aqueous solution was lyophilized and then used for the cellular internalization experiment.

For the investigation of the cellular internalization process, HeLa cells were cultured on a coverslip with a cell density of 2×10^4 cells. The next day, the cells were incubated with 5 μ g mL⁻¹ of FITC-tagged CD NPs. Another coverslip with untreated cells was kept as control. Cells were washed thrice with PBS after incubation and then fixed with 4% formaldehyde



for 10 min. The fixed cells were again washed with PBS and mounted on a glass slide with fluoroshield + DAPI-stained mounting media. The cellular internalization and distribution of FITC-labelled CD NPs in HeLa cells was visualized using a fluorescence microscope.

2.6. *In vitro* cell viability assay

The viability of HeLa cells and A549 cells after treatment with the NP construct was determined using an XTT-based cell viability assay according to the manufacturers' protocol. Cells (10^4 cells per well) were seeded in a 96-well plate as described above. The next day, cells were incubated with 1 and 1.5 mg mL^{-1} of Cyt *C*-loaded CD NPs, respectively, with and without co-treatment of chloroquine (0.1 mM) in serum-free DMEM media. 5 h after treatment, the cells were washed and the media was replaced with serum-supplemented DMEM media and incubated for a further 19 h. Afterwards, the cells were washed with PBS and XTT reagent mixture was added to each well followed by 3 h of incubation at 37°C . Absorbance was measured using a plate reader at 490 nm and the absorbance at 690 nm was used to subtract the background. The experiment was performed in triplicate, and the % cell viability was calculated as follows:

$$\% \text{ Cell viability} = \frac{\text{Absorbance of treated cells}}{\text{Absorbance of untreated cells}} \times 100$$

2.7. Studies to evaluate induction of apoptosis

2.7.1. Determination of apoptotic events and mitochondrial state using flow cytometric analysis. HeLa cells (0.5×10^6 cells per well) were seeded in a 6-well plate and kept overnight for growth. The next day, the cells were incubated with 1.5 mg mL^{-1} of Cyt *C*-loaded CD NPs along with chloroquine (0.1 mM) in serum-free DMEM media. 5 h after treatment, the cells were washed and replaced with serum-supplemented DMEM media and incubated for 6, 12 and 18 h. Following incubation, the cells were stained with dyes for various assays related to apoptosis. Annexin V/PI staining for determination of early and late apoptotic events in the cells and JC-1 dye for mitochondrial membrane depolarization assay, respectively, were performed according to the manufacturers' protocol and analyzed using a BD LSRFortessa flow cytometer in FITC and PI channel for annexinV/PI analysis and FITC and PE-Texas red for JC-1 analysis. Cells stained with only annexin V and PI were kept as positive control for compensation in flow cytometer of the annexin V and PI assays, respectively. Cells treated with CCCP provided with the kit were kept as a positive control for the JC-1 analysis.

2.7.2. Western blot analysis to determine activation of initiator protein for apoptosis. HeLa cells were seeded on a 6-well plate and kept overnight for growth. The next day, the cells were treated with three NP construct conditions. In one, only chloroquine (0.1 mM) was added. In another condition, cells were treated with Cyt *C*-loaded CD NPs (1.5 mg mL^{-1}) + chloroquine (0.1 mM). Untreated cells were kept as a control.

The treatment was given in serum-free media. 4 h post-treatment, the media was replaced with fresh serum-supplemented DMEM media. 6 h post-treatment, protein was extracted by lysing the cell in RIPA buffer, and estimation of protein was performed using the Bradford assay. Depending on the protein concentration, the samples were mixed with β -mercaptoethanol-supplemented sample gel-loading dye. The protein samples were then given a heat treatment at 95°C for 10 min. Next, the proteins were separated in an SDS-PAGE apparatus at 80 V for 2 h, following which the proteins were transferred onto a PVDF membrane in a transfer apparatus at 10 V for 2 h. Further, the membrane was blocked with 5% skim milk in TBST and incubated for 2 h. After blocking, the blots were incubated with the respective primary antibody (Caspase 9 and β actin) at 4°C overnight. Following incubation, the membrane was washed thrice (10 min) in TBST buffer and then incubated with horseradish peroxidase-conjugated secondary antibody for 2 h. Later, the membrane was washed thrice in TBST buffer. After washing, the chromogenic signal was detected by adding the colour-developing reagent (ECL substrate) while keeping in the dark for 5 min and then the bands were developed using a GelDoc system.

2.7.3. Fluorescence microscopic analysis of mitochondrial membrane depolarization. HeLa cells (2.5×10^4 cells) were seeded on poly-L-lysine-coated cover slips and kept overnight for growth. The next day, the cells were incubated with 1.5 mg mL^{-1} of Cyt *C*-loaded CD NPs along with chloroquine (0.1 mM) in serum-free DMEM media. 5 h after treatment, the cells were washed and the media was replaced with serum-supplemented DMEM media and incubated for 12 h in total. Following incubation, cells were fixed with 4% formaldehyde for 10 min. After washing three times with PBS, JC-1 dye was added according to the protocol and incubated for 30 min in a 5% CO_2 incubator at 37°C . The cells were then washed thrice with PBS and mounted on a glass slide with glycerol mounting media and visualized under a fluorescence microscope. Untreated cells were used as the experimental control.

2.7.4. Confocal microscopic analysis of nuclear fragmentation. 2.5×10^4 cells were seeded on poly-L-lysine-coated cover slips with complete media and kept overnight for growth and cells to adhere. The next day, the media was discarded and replaced with serum-free media with 1.5 mg mL^{-1} Cyt *C*-loaded CD NPs and 0.1 mM chloroquine. 5 h post-treatment, the media was replaced with fresh complete media and incubated for 12 h post-treatment. Then, the cells were washed thrice with PBS and fixed with 4% formaldehyde for 10 min. Finally, the cover slips containing the fixed cells were mounted onto glass slides using DAPI-containing mounting media for nucleus staining. The cells were visualized under a Nikon confocal fluorescence microscope. Untreated cells were kept as the experimental control.

2.7.5. Analysis of membrane blebbing of HeLa cells using SEM. Cells were seeded on a coverslip and treated with 1.5 mg mL^{-1} Cyt *C*-loaded CD NPs and 0.1 mM chloroquine similarly as mentioned above. After 12 h incubation, the cells were washed with PBS and fixed with 4% glutaraldehyde at 4°C





Fig. 1 Characterization of the Cyt *C*-loaded CD NPs. (a) Zeta potential measurements of cytochrome *C* and CD polymer at pH 7.4 and pH 11. (b) SEM and (c) AFM images of Cyt *C*-loaded CD NPs.

for 2 h. Next, the fixed cells were dehydrated using ethanol gradient. Finally, the dehydrated cells were air-dried and coated with gold film, and visualized under a scanning electron microscope (Nova Nano SEM450, FEI).

3. Results and discussion

3.1. Synthesis and characterization of Cyt *C*-encapsulated CD NPs

Cationic dextrin nanoparticles were prepared following a protocol of ionic gelation using quaternary dextrin and TPP, as previously reported by our group but with modifications.³¹ The process involves complexation of positively charged quaternarized dextrin with negatively charged TPP molecules, leading to the formation of spherical nanoparticles. The therapeutic protein, Cyt *C*, was loaded on the CP NPs during the synthesis of the CD NPs. However, the synthesis was carried out at pH 11 instead of physiological pH. This change in pH was done to enable the encapsulation of the protein within the CD NPs. The protein Cyt *C* has a pI of 10.8 and possesses a net positive charge at physiological pH due to the presence of lysine residues.^{15,32,38} As a result, the positively charged Cyt *C* could not interact efficiently with the quaternized dextrin due to similar charges at physiological pH and was not encapsulated. Hence, the protein Cyt *C* was suspended in a buffer of pH 11, above the isoelectric point of Cyt *C*, rendering a net negative

charge to Cyt *C*. The surface charges of Cyt *C* and CD polymer were quantified at buffers of pH 7.4 and pH 11 using a zeta sizer and the results are shown in Fig. 1(a). Cyt *C* possess a net positive charge at pH 7.4; however, it has a net negative charge at pH 11. At pH 11, there was a slight decrease in the zeta potential of CD from pH 7.4, but it still possesses a net positive charge. Thus, the synthesis of the CD NPs was carried out at pH 11 where Cyt *C* was added, which can now interact with the oppositely charged CD and get encapsulated in the NPs during the process of ionic gelation using TPP as the anionic cross-linker. The prepared CD NPs were then characterized using SEM and AFM and the corresponding images are shown in Fig. 1(b) and (c), respectively. Uniformly distributed NPs were observed in both the SEM and AFM images with an average size of 100 ± 30 nm. NTA analysis of the prepared CD NPs demonstrated a hydrodynamic diameter of 98 nm (mode) with a PDI of 0.19 (Fig. S1, ESI[†]). The zeta potential of the Cyt *C*-loaded CD NPs was determined to be +6.3 mV.

3.2. Cytochrome *C* loading and release from CD NPs

Cyt *C* has a characteristic absorption at 409 nm which allows for the quantification of the protein in a sample (Fig. 2(a)). A standard plot for Cyt *C* was prepared by taking the absorption of varying concentration of the protein Cyt *C*. The CD NPs do not have any significant absorbance at 409 nm (Fig. 2(a)) and the amount of Cyt *C* loaded into the nanoparticles was




Fig. 2 Evaluating the loading and release of cytochrome *C* in CD NPs: (a) UV-visible absorption spectra of Cyt *C*, CD NPs and Cyt *C*-loaded CD NPs. (b) pH-dependent Cyt *C* release from CD NPs at physiological pH (7.4) and acidic pH (5.5).






Fig. 3 Characterization of the protein released from CD NPs. (a) Near-UV CD spectra of Cyt *C* released from CD NPs and free Cyt *C* at various pH conditions. (b) Enzyme kinetics study of native and released Cyt *C* for the oxidation of ABTS substrate.

determined based on the absorbance of the Cyt *C*-loaded CD NPs. The loading efficiency was calculated using a standard curve (Fig. S2, ESI[†]) and was found to be $\sim 20\%$.

Consequently, we investigated the release of Cyt *C* from the CD NPs through a dynamic dialysis technique using a dialysis membrane (MWCO: 100 kD). The membrane containing Cyt *C*-encapsulated CD NPs were suspended in buffers at two different pH, 7.4 and 5.5, which mimic the physiological pH and the acidic endosome pH, respectively.³⁹ The amount of Cyt *C* released in the aqueous media was estimated by monitoring the absorbance of Cyt *C* at 409 nm through UV-vis spectroscopy (Fig. 2(b)). At both pH, there was an increase in the cumulative release of the drug with time. However, at acidic pH 5.5, the release of Cyt *C* was more with $\sim 40\%$ of Cyt *C* released within 30 min, whereas only $\sim 25\%$ was released within 30 min at pH of 7.4. Almost 90% of the protein was released within 24 h, at pH 5.5, whereas $\sim 75\%$ of Cyt *C* was released at pH 7.4 in 24 h, which is a lot less than that released at the acidic pH. Since the encapsulation of Cyt *C* was carried out at a higher pH in order to achieve better encapsulation due to the charge reversal of Cyt *C* above its pI, when the NPs encounter a buffer with lower pH than its pI, the surface charge of the Cyt *C* changes, which leads to destabilization in the electrostatic interaction with the cationic dextrin polymer, leading to its release from the CD NPs into the aqueous medium. This justifies the higher release of Cyt *C* at pH 5.5 as compared to pH 7.4.

3.3. Structural and functional stability of cytochrome *C* before and after release

The structural and functional stability of the released Cyt *C* was investigated using circular dichroism and enzyme kinetics study. Fig. 3(a) shows the CD spectra of free Cyt *C* and that released from the CD NPs. The near-UV CD spectrum (190–320 nm) provides information on the tertiary structure of the protein. The spectrum of Cyt *C* in this range is mainly contributed by four Phe residues, four Tyr residues, one Trp residue, and two thioether bonds. There are two minima at 210 and 223 nm in the near-UV CD spectrum of native Cyt *C*,

which correspond to Trp-59.¹ The Cyt *C* released at pH 5.5 after 24 h also exhibited two minima at 210 and 223 nm, which clearly demonstrated that the structure of the Cyt *C* remained unchanged. This confirms the structural stability of the released Cyt *C*, which did not undergo any conformational change during the loading and the release process.

Further, it is prerequisite for a protein to remain functionally active after encapsulation and release from NPs for therapeutic applications. In order to investigate the functional activity of the released Cyt *C*, we estimated its enzymatic activity by means of ABTS (2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) oxidation assay and compared it with that of free Cyt *C*. Fig. 3(b) illustrates the formation of oxidised ABTS with respect to time monitored using UV-vis spectroscopy. Free Cyt *C* clearly shows an increase in the product formation as indicated by the rise in absorbance at 430 nm. The released Cyt *C* also demonstrated a clear increase in absorbance at 430 nm with respect to time, clearly demonstrating its activity in the oxidation of ABTS. The CD NPs did not show any absorbance rise, demonstrating that they do not possess any enzymatic activity. These results clearly validated the functional activity of the released Cyt *C*.

3.4. Cellular internalization of FITC-conjugated CD NPs

Being positively charged, CD NPs are expected to accelerate the process of cellular entry. In the present study, the cellular uptake of CD NPs was evaluated using fluorescence microscopy. To execute the internalization process, CD NPs were conjugated with a fluorescent dye, FITC, to visualize the uptake of the NPs. HeLa cells were treated with $5 \mu\text{g mL}^{-1}$ of FITC-conjugated CD NPs for 6 h. Following incubation, the cells were stained with DAPI and observed under a fluorescence microscope. The control untreated cells showed no green fluorescence; however, blue DAPI-stained nuclei were clearly observed (Fig. 4). Conversely, the FITC-labelled CD NP-treated cells showed the presence of green fluorescence around the blue DAPI-stained nuclei, thus demonstrating the successful internalization of FITC-labelled CD NPs inside the cells.





Fig. 4 Determination of *in vitro* cellular internalization of FITC-conjugated CD NPs ($5 \mu\text{g mL}^{-1}$) in HeLa cells at 6 h. Visualized under fluorescence microscope. The upper panel is untreated control cells and the lower panel shows cells 6 h post-treatment, where blue fluorescence corresponds to DAPI-stained nuclei and green fluorescence corresponds to FITC-conjugated CD NPs. Images were captured at $60\times$ objective. Scale bar: $20 \mu\text{m}$.

3.5. *In vitro* cell viability assay

After confirming the functional and structural stability of the released Cyt *C*, we attempted to assess the effect of Cyt *C* in inducing cell death upon its delivery using CD NPs post-CQ treatment using XTT-based cell viability assay. Firstly, HeLa cells were treated with varying concentrations of only Cyt *C* (10 – $250 \mu\text{g mL}^{-1}$) for 24 h to understand if free Cyt *C* can be taken up by cells and induce cell death. The cell viability assay showed that there was no significant cell death (Fig. 5(a)) and the overall viability remained above 98%. This suggested that Cyt *C* was unable to show any toxic effect, which can be attributed to the impermeability cell membrane to the protein due to its macromolecular form. The cells treated with Cyt *C*-loaded CD NPs also did not show any significant toxicity when treated at concentrations of 1 and 1.5 mg mL^{-1} for 24 h. This was due to the endosomal entrapment of the protein Cyt *C*, which was not released into the cell cytoplasm and thus could not induce apoptosis. The Cyt *C* entrapped within the endosome is subsequently degraded upon maturation of the endosome to an endolysosome. In order to let the CD NPs-Cyt *C* release into the cell cytosol, the drug CQ was employed, which is known to act as an endosomal disruptor. Though CQ is a

well-known antimalarial drug that has been in use for a long time, recently it has been the prime focus for increasing the process of ‘endosomal escape’ in cancer therapy.³⁴ Chloroquine, being a very small molecule, can easily enter into cells and its basic nature also helps them to enter inside the endosome.⁴⁰ Upon entering the acidic endosome, it will itself get protonated and sequester protons. H^+ ions are thus recruited within the endosome through an ATPase proton channel situated at the periphery of the endosomal membrane. As a result, chloride ions will also accompany and accumulate within endosomes and together will lead to increased osmotic pressure. Subsequently, diffusion of water into the endosome will occur, which will lead to swelling and rupture of the endosomal membrane, followed by release of the entrapped materials into the cytosol. This whole process is termed the ‘proton sponge effect’.^{41,42} Hence, we investigated the viability of cells by co-delivering CQ (0.1 mM) along with Cyt *C*-encapsulated CD NPs to HeLa cells. A drastic reduction in the percentage of viable cells was observed for both the treated concentrations with 46% cell death at 1 mg mL^{-1} and 88% at 1.5 mg mL^{-1} which is evident from Fig. 5(b). Interestingly, cells treated with only CQ (0.1 mM) exhibited no cytotoxicity.



Fig. 5 *In vitro* cell viability assay of HeLa cells treated with different concentration of (a) Cyt *C* and (b) Cyt *C*-loaded CD NPs with and without chloroquine. Data presented as mean \pm SD (** $p < 0.01$, *** $p < 0.001$, and **** $p < 0.0001$).



Additionally, we investigated the viability of cells treated with Cyt *C* + CQ (0.1 mM) at various Cyt *C* concentrations, the range of which is equivalent to the loaded concentration within the CD NPs. 24 h post-treatment, cell viability remained above 94% (Fig. S3, ESI[†]), indicating that Cyt *C* + CQ was not able to cause cell death. Therefore, it can be established from the results that the CD NPs as a delivery vehicle aided Cyt *C* in cellular uptake, whereas CQ on the other hand enabled the Cyt *C*-CD NP construct to escape from the endosome into the cytosol without causing any cytotoxicity. Overall, the cell death upon treatment with CD NPs-Cyt *C* and CQ can be attributed to the action of released Cyt *C*.

Besides HeLa cells, cell viability assay was also performed in A549 cells (lung carcinoma epithelial cells) to validate the strategy of cellular toxicity using CD NPs-Cyt *C* with and without the use of CQ. The results shown in Fig. S4 (ESI[†]) indicate ~30% cell death after treating with 1 mg mL⁻¹ of Cyt *C*-encapsulated CD NPs + CQ and ~60% cell death at 1.5 mg mL⁻¹ treated concentration, thus exhibiting the generality of the strategy where the cell death action is due to the released Cyt *C* along with CQ as an endosomal escape agent.

3.6. Studies on induction of apoptosis

3.6.1. Annexin V/PI staining. The cell viability results explain the contribution of Cyt *C* towards cell death. However, it is crucial to confirm that the cell death occurred due to Cyt *C* following apoptosis. As Cyt *C* is considered as an initiator candidate for activation of apoptosis through the caspase cascade, we performed a couple of experiments to validate this. Usually cells that undergo apoptosis exhibit unique characteristics, such as flip-flop of phosphatidylserine, nuclear fragmentation, mitochondrial depolarization, and membrane blebbing. First and foremost, we performed an annexin V-FITC/PI staining assay using a flow cytometer to check if the Cyt *C* delivery induced apoptosis. In general, during the early stages of apoptosis, a change in the plasma membrane of cells occurs that is accompanied with the loss of phospholipid asymmetry. This results in exposure of plasma membrane-bound phosphatidylserine (PS) to the outer surface. Annexin V, a protein, has a strong affinity towards PS. Therefore, when fluorophore FITC-tagged annexin V binds to the exposed PS, the percentage of cells in the early apoptotic phase of cell death⁴³ can be determined using flow cytometry. Similarly, propidium iodide (PI) is a membrane-impermeable dye that penetrates only compromised cells that have lost their membrane integrity and binds to nucleic acids. Cells in the late phase of apoptosis or towards the dead phase can easily be quantified by measuring the fluorescence of PI.⁴⁴ Thus, in the present case, the percentage of apoptotic cells was quantified by dual staining both treated and untreated HeLa cells with annexin V-FITC/PI and quantifying using a flow cytometer, as shown in Fig. 6(a) and (b). The results show that a concentration of 1.5 mg mL⁻¹ of Cyt *C*-encapsulated CD NPs in combination with 0.1 mM CQ induced ~8% early apoptotic and ~12% late apoptotic events towards HeLa cells after 6 h of incubation. The percentage of cells in the early apoptotic phase increased to ~30% after 12 h




Fig. 6 Evaluation of apoptotic events in HeLa cells. (a) Flow cytometric analysis of HeLa cells treated with 1.5 mg mL⁻¹ Cyt *C*-loaded CD NPs in combination with chloroquine (0.1 mM) using annexin V/PI staining. (b) Graphical representation of the flow cytometry data. Data presented as mean \pm SD (** p < 0.01, *** p < 0.001, and **** p < 0.0001).

of incubation. After 18 h incubation, the amount of early apoptotic cells reduced to 16% since ~75% of cells were in the late apoptotic phase. In contrast, about 89% of



Fig. 7 Evaluation of caspase-9 activation upon treatment with Cyt *C*-CD NPs in HeLa cells through western blot analysis. From left to right: control (without any treatment), CQ-treated, and treated with 1.5 mg mL⁻¹ Cyt *C*-loaded CD NPs in combination with chloroquine (0.1 mM).



chloroquine-treated cells were live even after 18 h of incubation, which is comparable to the control untreated cells. Altogether, Cyt *C*-encapsulated CD NPs with co-delivery of CQ proved beneficial as a delivery vehicle in efficient cellular internalization and endosomal escape leading to cancer cell death. It is to be noted that the used concentration of CQ produced no signs of apoptosis.

3.6.2. Correlation between activation of caspase-9 and mitochondrial membrane depolarization. The apoptotic process involves mitochondrial membrane depolarization, which facilitates the release of Cyt *C* from the inner mitochondrial

membrane into the cytosol, where it binds to Apaf-1 (apoptotic protease activating factor-1) and further activates the effector caspases.¹ Hence, this is true only when there is any external apoptotic stimulus. Therefore, the question arises of what happens to the mitochondrial membrane potential ($\Delta\Psi_M$) when Cyt *C* is directly administered into the cytosol from an external source? Reports suggests that there are two ways by which mitochondrial permeabilization occurs.⁴⁵ One is the formation of pores with recruitment of anti- and pro-apoptotic proteins. Second, a direct connection has been postulated between activated caspases with the formation of



Fig. 8 Mitochondrial depolarization assay. (a) Flow cytometric analysis of mitochondrial state of HeLa cells treated with 1.5 mg mL^{-1} Cyt *C*-loaded CD NPs in combination with chloroquine (0.1 mM) using JC-1 dye. The green colour represents the J-monomers and the red colour represents the J-aggregates. (b) Graphical representation of the flowcytometric data. Data presented as mean \pm SD (** $p < 0.01$, *** $p < 0.001$, and **** $p < 0.0001$).



transient pores in mitochondrial membrane.⁴⁵ Reports also suggest that the effector caspases not only serve the role of an apoptosis executioner, but also help in opening of the mitochondrial permeability transient pore complex (PTPC).^{46,47} This PTPC is a multiprotein complex located at the contact site of the inner and outer mitochondrial membrane. Upon interaction with active caspases, it forms a pore in the mitochondrial membrane with the loss of mitochondrial membrane potential $\Delta\Psi_M$.^{46,47} Therefore, we hypothesize in our study that the externally administered Cyt *C* will have a rapid onset time for apoptosis by directly binding to Apaf-1 and activating the caspase cascade (caspase 9 and 3).⁴⁸ Simultaneously, the activated caspases will promote pore formation in the mitochondria through PTPC opening and there will be a subsequent membrane depolarization. To confirm our hypothesis, we examined the expression of caspase-9, which is the initiator protein for the apoptosis pathway, through western blot analysis in HeLa cells after treating with the CD NPs-Cyt *C* + CQ. Usually, the Cyt *C* in the cytosol activates Apaf-1 (apoptotic protease activating factor-1), which in turn activates procaspase-9 by cleaving the protein between a larger and a smaller subunit and forms a complex known as an apoptosome.⁴⁹ Interestingly, within 6 h after treatment, the expression of cleaved counterparts of caspase-9 protein at 37 kDa and 35 kDa MW was clearly observed, as evident from Fig. 7, suggesting activation of the caspase cascade. However, in the control and CQ-treated cells, majorly full-length caspase-9 protein expression was observed. Hence, western blot analysis proved the activation of caspases within 6 h of treatment. The expression of β -actin, a housekeeping gene used as a control, did not change across the differently treated samples.

Next, we examined the mitochondrial membrane potential ($\Delta\Psi_M$) at various time intervals post-treatment with CD NPs-Cyt *C* + CQ using the dye JC-1. JC-1 is a cationic lipophilic dye that emits green fluorescence in its monomeric form. JC-1 can selectively enter intact mitochondria and accumulate at a high concentration, leading to the formation of a reversible complex

known as J-aggregates. In contrast with JC-1 monomeric form, J-aggregates exhibit red fluorescence. When there is a decrease in $\Delta\Psi_M$, the formation of J-aggregates will decrease and most of the dye will remain in its monomeric form, emitting green fluorescence. Thus, based on the permeation of the JC1 dye and its red/green fluorescence, the state of the mitochondrial membrane potential can be assessed. In our study, the untreated and CQ-treated HeLa cells exhibited more than 90% red fluorescence attributed to J-aggregates and a healthy condition of the cells as observed through flow cytometry analysis (Fig. 8(a) and (b)), whereas cells treated with Cyt *C*-encapsulated CD NPs in combination with CQ exhibited a decrease in the red fluorescence with time. The red fluorescence decreased from 80% to 70% to 50% after 6 h, 12 h and 18 h of treatment, respectively. Thus, a time-dependent decrease in percentage of red fluorescence and corresponding increase in green fluorescence suggested a time-dependent depolarization of $\Delta\Psi_M$. Overall, this confirms mitochondrial membrane depolarization when Cyt *C* is administered externally, leading to apoptosis.

Fluorescence microscopy for the same was performed and the extent of red and green fluorescence after CD NPs-Cyt *C* + CQ treatment was observed. The colocalised image of the control untreated cells, as depicted in Fig. 9, displays a yellowish colour that corresponds to the presence of both JC-1 monomers and a high concentration of J-aggregates, whereas in treated cells, a decrease in red fluorescence was observed with more green fluorescence, which corroborates the loss of $\Delta\Psi_M$. The overall findings suggest that depolarization of the mitochondrial membrane occurred upon treatment.

3.6.3. Apoptotic nuclear fragmentation analysis through fluorescence microscope. Nuclear fragmentation and chromatin condensation is another hallmark of apoptosis.^{8,39} Accordingly, we examined the nuclear morphology of the untreated and treated HeLa cells stained with DAPI. The confocal microscopic images (Fig. 10(c) and (d)) show a clear granular appearance and the loss of nuclear membrane integrity in the cells




Fig. 9 Confocal microscopic images for the visualization of mitochondrial membrane depolarization in HeLa cells after treatment with CD NPs-Cyt *C* + CQ using the dye JC-1. The top panel represents the control HeLa cells and the bottom panel represents the HeLa cells treated with 1.5 mg mL⁻¹ Cyt *C*-loaded CD NPs in combination with chloroquine (0.1 mM).





Fig. 10 Nuclear fragmentation and membrane blebbing analysis. Confocal microscopic images showing nuclear fragmentation of HeLa cells stained with DAPI: (a) and (b) Untreated control cells and (c) and (d) cells treated with 1.5 mg mL^{-1} Cyt *C*-loaded CD NPs in combination with chloroquine (0.1 mM). Visualization of plasma membrane blebbing of HeLa cells showing apoptosis using SEM: (e) untreated control cells and (f) cells treated with 1.5 mg mL^{-1} Cyt *C*-loaded CD NPs in combination with chloroquine (0.1 mM).

treated with Cyt *C*-CD NPs + CQ, whereas untreated cells revealed an intact nuclear morphology with intact nucleolus that is clearly visible in Fig. 10(a) and (b). This clearly demonstrates the induction of apoptosis in HeLa cells upon treatment.

3.6.4. Visualization of cell-membrane blebbing as a consequence of apoptosis using SEM. A unique characteristic of apoptosis is the formation of apoptotic bodies through blebbing of the plasma membrane. Therefore, we performed SEM analysis to visualize the cellular surface morphology before and after treatment. As shown in Fig. 10(e), a perfectly extended and stretched surface morphology of the control HeLa cells was observed, indicating the healthy status of the cells, whereas cells treated with CD NPs-Cyt *C* + CQ (Fig. 10(f)) showed the distinctive appearance of apoptotic bodies with extensive membrane blebbing. The membrane damage was also evident from the shrunken and round shaped cells with cytoplasmic constrictions. Thus, the overall studies taken together elucidate apoptosis as the mechanism of cell death contributed by the delivered Cyt *C*.

4. Conclusion

Ensuring compatibility between the engineered delivery system and the therapeutic cargo without affecting its activity and stability is a significant challenge in protein delivery. In this study, we developed a biocompatible and biodegradable NP construct using material obtained from natural sources. The CD NPs were synthesized using ionic gelation and encapsulated with the therapeutic protein Cyt *C*. Co-delivery of CQ, a drug that enhances endosomal release through the proton sponge effect, was used to overcome the challenge of inefficient release of the therapeutic cargo from endosomes. The bioactivity of the intracellular released Cyt *C* was maintained even in acidic pH.

Our experimental findings suggest that externally administered Cyt *C* rapidly activates the caspase-9 protein and helps in the formation of pores in the mitochondria, leading to a decrease in mitochondrial membrane potential and ultimately inducing apoptosis. This approach offers a simple strategy for developing a delivery system for efficient encapsulation and direct delivery of therapeutic proteins to overcome the challenges posed by resistant cancer cells that inhibit the release of Cyt *C* upon stimulus.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

The authors acknowledge support from the BioX centre and the Advanced Materials Research Centre (AMRC), Indian Institute of Technology Mandi for research and infrastructure facility. AS and SS acknowledge MoE and PMRF, respectively, for providing doctoral fellowships. The scheme and TOC images were prepared using Biorender.com and the authors acknowledge it.

References

- 1 J. Méndez, M. Morales Cruz, Y. Delgado, C. M. Figueroa, E. A. Orellano and M. Morales, *et al.*, Delivery of chemically glycosylated cytochrome *c* immobilized in mesoporous silica nanoparticles induces apoptosis in HeLa cancer cells, *Mol. Pharmaceutics*, 2014, **11**(1), 102–111.
- 2 Radiation therapy side effects. NIH, Available from: <https://www.cancer.gov/about-cancer/treatment/types/radiation-therapy/side-effects>.



- 3 G. Muthiah and A. Jaiswal, Can the Union of Prodrug Therapy and Nanomedicine Lead to Better Cancer Management?, *Adv. NanoBiomed Res.*, 2022, **2**(1), 2100074.
- 4 S. N. Bhatia, X. Chen, M. A. Dobrovolskaia and T. Lammers, Cancer nanomedicine, *Nat. Rev. Cancer*, 2022, **22**(10), 550–556.
- 5 M. J. Nirmala, U. Kizhuveetil, A. Johnson, G. Balaji, R. Nagarajan and V. Muthuvijayan, Cancer nanomedicine: a review of nano-therapeutics and challenges ahead, *RSC Adv*, 2023, **13**(13), 8606–8629.
- 6 R. Khandelia, A. Jaiswal, S. S. Ghosh and A. Chattopadhyay, Gold nanoparticle–protein agglomerates as versatile nanocarriers for drug delivery, *Small*, 2013, **9**(20), 3494–3505.
- 7 R. Khandelia, A. Jaiswal, S. S. Ghosh and A. Chattopadhyay, Polymer coated gold nanoparticle–protein agglomerates as nanocarriers for hydrophobic drug delivery, *J. Mater. Chem. B*, 2014, **2**(38), 6472–6477.
- 8 S. Roy, A. Sarkar and A. Jaiswal, Poly (allylamine hydrochloride)-functionalized reduced graphene oxide for synergistic chemo-photothermal therapy, *Nanomedicine*, 2019, **14**(3), 255–274.
- 9 P. Singh, P. Haloi, K. Singh, S. Roy, A. Sarkar and R. Choudhary, *et al.*, Palladium Nanocapsules for Photothermal Therapy in the Near-Infrared II Biological Window, *ACS Appl. Mater. Interfaces*, 2023, **15**(33), 39081–39098.
- 10 M. Majidinia, M. Mirza-Aghazadeh-Attari, M. Rahimi, A. Mihanfar, A. Karimian and A. Safa, *et al.*, Overcoming multidrug resistance in cancer: Recent progress in nanotechnology and new horizons. *IUBMB, Life*, 2020, **72**(5), 855–871.
- 11 S. Li, J. Zhang, C. Deng, F. Meng, L. Yu and Z. Zhong, *et al.*, Redox-sensitive and intrinsically fluorescent photoclick hyaluronic acid nanogels for traceable and targeted delivery of cytochrome *c* to breast tumor in mice, *ACS Appl. Mater. Interfaces*, 2016, **8**(33), 21155–21162.
- 12 R. Baskar, K. A. Lee, R. Yeo and K.-W. Yeoh, Cancer and radiation therapy: current advances and future directions, *Int. J. Med. Sci.*, 2012, **9**(3), 193.
- 13 C. Xu, C. Lei and C. Yu, Mesoporous silica nanoparticles for protein protection and delivery, *Front. Chem.*, 2019, **7**, 290.
- 14 X. S. Sun, M.-S. Jang, Y. Fu, J. H. Lee, D. S. Lee and Y. Li, *et al.*, Intracellular delivery of cytochrome *C* using hypoxia-responsive polypeptide micelles for efficient cancer therapy, *Mater. Sci. Eng., C*, 2020, **114**, 111069.
- 15 L. J. Delinois, O. De León-Vélez, A. Vázquez-Medina, A. Vélez-Cabrera, A. Marrero-Sánchez and C. Nieves-Escobar, *et al.*, Cytochrome *c*: Using Biological Insight toward Engineering an Optimized Anticancer Biodrug, *Inorganics*, 2021, **9**(11), 83.
- 16 H. Chang, J. Lv, X. Gao, X. Wang, H. Wang and H. Chen, *et al.*, Rational design of a polymer with robust efficacy for intracellular protein and peptide delivery, *Nano. Lett.*, 2017, **17**(3), 1678–1684.
- 17 S. K. Kim, M. B. Foote and L. Huang, The targeted intracellular delivery of cytochrome *C* protein to tumors using lipid-apolipoprotein nanoparticles, *Biomaterials*, 2012, **33**(15), 3959–3966.
- 18 S. Hong, D. W. Choi, H. N. Kim, C. G. Park, W. Lee and H. H. Park, Protein-based nanoparticles as drug delivery systems, *Pharmaceutics*, 2020, **12**(7), 604.
- 19 F. Moncalvo, M. I. Martinez Espinoza and F. Cellesi, Nano-sized delivery systems for therapeutic proteins: Clinically validated technologies and advanced development strategies, *Front. Bioeng. Biotechnol.*, 2020, **8**, 89.
- 20 M. J. Mitchell, M. M. Billingsley, R. M. Haley, M. E. Wechsler, N. A. Peppas and R. Langer, Engineering precision nanoparticles for drug delivery, *Nat. Rev. Drug Discovery*, 2021, **20**(2), 101–124.
- 21 M. Morales-Cruz, A. Cruz-Montañez, C. M. Figueroa, T. González-Robles, J. Davila and M. Inyushin, *et al.*, Combining stimulus-triggered release and active targeting strategies improves cytotoxicity of cytochrome *c* nanoparticles in tumor cells, *Mol. Pharmaceutics*, 2016, **13**(8), 2844–2854.
- 22 L. Liguori, B. Marques, A. Villegas-Mendez, R. Rothe and J.-L. Lenormand, Liposomes-mediated delivery of proapoptotic therapeutic membrane proteins, *J. Controlled Release*, 2008, **126**(3), 217–227.
- 23 I. Dominguez-Martinez, F. Joaquin-Ovalle, Y. Ferrer-Acosta and K. H. Griebenow, Folate-decorated cross-linked cytochrome *c* nanoparticles for active targeting of non-small cell lung carcinoma (NSCLC), *Pharmaceutics*, 2022, **14**(3), 490.
- 24 E. Choi, D.-K. Lim and S. Kim, Hydrolytic surface erosion of mesoporous silica nanoparticles for efficient intracellular delivery of cytochrome *c*, *J. Colloid Interface Sci.*, 2020, **560**, 416–425.
- 25 B. Zhang, Z. Luo, J. Liu, X. Ding, J. Li and K. Cai, Cytochrome *c* end-capped mesoporous silica nanoparticles as redox-responsive drug delivery vehicles for liver tumor-targeted triplex therapy in vitro and in vivo, *J. Controlled Release*, 2014, **192**, 192–201.
- 26 C. Guo, Y. Zhang, Y. Li, L. Zhang, H. Jiang and J. Tao, *et al.*, Gold nanoparticle-guarded large-pore mesoporous silica nanocomposites for delivery and controlled release of cytochrome *c*, *J. Colloid Interface Sci.*, 2021, **589**, 34–44.
- 27 D. Hreczuk-Hirst, D. Chicco, L. German and R. Duncan, Dextrins as potential carriers for drug targeting: tailored rates of dextrin degradation by introduction of pendant groups, *Int. J. Pharm.*, 2001, **230**(1–2), 57–66.
- 28 A. Jaiswal, A. Chattopadhyay and S. S. Ghosh, Functional chitosan nanocarriers for potential applications in gene therapy, *Mater. Lett.*, 2012, **68**, 261–264.
- 29 Y. Han, J. Zhou, Y. Hu, Z. Lin, Y. Ma and J. J. Richardson, *et al.*, Polyphenol-based nanoparticles for intracellular protein delivery via competing supramolecular interactions, *ACS Nano*, 2020, **14**(10), 12972–12981.
- 30 D. M. Silva, C. Nunes, I. Pereira, A. S. Moreira, M. R. M. Domingues and M. A. Coimbra, *et al.*, Structural analysis of dextrins and characterization of dextrin-based biomedical hydrogels, *Carbohydr. Polym.*, 2014, **114**, 458–466.
- 31 A. Sarkar, S. Roy, P. Bhatia and A. Jaiswal, Quaternary ammonium substituted dextrin-based biocompatible cationic nanoparticles with ultrahigh pH stability for drug delivery, *J. Appl. Polym. Sci.*, 2023, **140**(11), e53626.



- 32 S. Santra, C. Kaittanis and J. M. Perez, Cytochrome *C* encapsulating theranostic nanoparticles: a novel bifunctional system for targeted delivery of therapeutic membrane-impermeable proteins to tumors and imaging of cancer therapy, *Mol. Pharmaceutics*, 2010, **7**(4), 1209–1222.
- 33 M. Saxena, Y. Delgado, R. K. Sharma, S. Sharma, S. L. P. D. L. Guzmán and A. D. Tinoco, *et al.*, Inducing cell death in vitro in cancer cells by targeted delivery of cytochrome *c* via a transferrin conjugate, *PLoS One*, 2018, **13**(4), e0195542.
- 34 M. Hajimolaali, H. Mohammadian, A. Torabi, A. Shirini, M. Khalife Shal and H. B. Nezhad, *et al.*, Application of chloroquine as an endosomal escape enhancing agent: new frontiers for an old drug, *Expert Opin. Drug Delivery*, 2021, **18**(7), 877–889.
- 35 S. Roy, M. Kumari, P. Haloi, S. Chawla, V. B. Konkimalla and A. Kumar, *et al.*, Quaternary ammonium substituted pullulan accelerates wound healing and disinfects *Staphylococcus aureus* infected wounds in mouse through an atypical ‘non-pore forming’ pathway of bacterial membrane disruption, *Biomater. Sci.*, 2022, **10**(2), 581–601.
- 36 S. Roy, P. Haloi, R. Choudhary, S. Chawla, M. Kumari and V. B. Konkimalla, *et al.*, Quaternary Pullulan-Functionalized 2D MoS₂ Glycosheets: A Potent Bactericidal Nanoplatform for Efficient Wound Disinfection and Healing, *ACS Appl. Mater. Interfaces.*, 2023, **15**(20), 24209–24227, DOI: [10.1021/acscami.3c04390](https://doi.org/10.1021/acscami.3c04390).
- 37 I. I. Slowing, B. G. Trewyn and V. S.-Y. Lin, Mesoporous silica nanoparticles for intracellular delivery of membrane-impermeable proteins, *J. Am. Chem. Soc.*, 2007, **129**(28), 8845–8849.
- 38 A. Maccone, S. Masciarelli, F. Palombarini, D. Quaglio, A. Boffi and M. C. Trabuco, *et al.*, Ferritin nanovehicle for targeted delivery of cytochrome *C* to cancer cells, *Sci. Rep.*, 2019, **9**(1), 1–7.
- 39 A. Sarkar, S. Roy, P. Sanpui and A. Jaiswal, Plasmonic Gold Nanorattle Impregnated Chitosan Nanocarrier for Stimulus Responsive Theranostics, *ACS Appl. Bio Mater.*, 2019, **2**(11), 4812–4825.
- 40 M. A. A. Al-Bari, Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases, *Pharmacol. Res. Perspect.*, 2017, **5**(1), e00293.
- 41 A. K. Varkouhi, M. Scholte, G. Storm and H. J. Haisma, Endosomal escape pathways for delivery of biologicals, *J. Controlled Release*, 2011, **151**(3), 220–228.
- 42 B. Zhang and S. Mallapragada, The mechanism of selective transfection mediated by pentablock copolymers; Part II: Nuclear entry and endosomal escape, *Acta Biomater.*, 2011, **7**(4), 1580–1587.
- 43 M. Van Engeland, L. J. Nieland, F. C. Ramaekers, B. Schutte and C. P. Reutelingsperger, Annexin V-affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure, *Cytometry*, 1998, **31**(1), 1–9.
- 44 C. Riccardi and I. Nicoletti, Analysis of apoptosis by propidium iodide staining and flow cytometry, *Nat. Protoc.*, 2006, **1**(3), 1458–1461.
- 45 C. Garrido, L. Galluzzi, M. Brunet, P. Puig, C. Didelot and G. Kroemer, *et al.*, Mechanisms of cytochrome *c* release from mitochondria, *Cell Death Differ.*, 2006, **13**(9), 1423–1433.
- 46 I. Marzo, C. Brenner, N. Zamzami, S. A. Susin, G. Beutner and D. Brdiczka, *et al.*, The permeability transition pore complex: a target for apoptosis regulation by caspases and Bcl-2-related proteins, *J. Exp. Med.*, 1998, **187**(8), 1261–1271.
- 47 T. Xia, C. Jiang, L. Li, C. Wu, Q. Chen and S.-S. Liu, A study on permeability transition pore opening and cytochrome *c* release from mitochondria, induced by caspase-3 in vitro, *FEBS Lett.*, 2002, **510**(1–2), 62–66.
- 48 V. Barcelo-Bovea, I. Dominguez-Martinez, F. Joaquin-Ovalle, L. A. Amador, E. Castro-Rivera and K. Medina-Álvarez, *et al.*, Optimization and characterization of protein nanoparticles for the targeted and smart delivery of cytochrome *c* to non-small cell lung carcinoma, *Cancers*, 2020, **12**(5), 1215.
- 49 L. J. Pagliari, M. J. Pinkoski and D. R. Green, Apoptosis signaling: a means to an end, *Handbook of Cell Signaling*, Elsevier, 2010, pp. 2535–2543.

